Educational reference only. Informational material drawn from peer-reviewed literature. Not medical advice and not a recommendation to use, dose, or modify any therapy. Decisions about hormone therapy should be made with a qualified healthcare provider.
Overview
Overview
Thymosin alpha-1 (Tα1), marketed internationally under the trade name Zadaxin (thymalfasin), is a synthetic 28-amino acid peptide with an unusual regulatory and clinical position. It is approved in over 35 countries for chronic hepatitis B, hepatitis C, and various immunodeficiency conditions, with substantial controlled clinical trial evidence including multiple randomized controlled trials, meta-analyses, and over 30 clinical trials involving more than 11,000 human subjects.
Despite this evidence base, the compound has never received FDA approval in the United States, a regulatory gap that reflects commercial calculations rather than scientific safety concerns.
Thymosin alpha-1 is identical in sequence to a naturally occurring peptide produced by the thymus gland. It is one of the most thoroughly characterized immunomodulator peptides in clinical use globally, with a mechanism centered on restoration of impaired immune responses rather than general immune stimulation. This positions it as fundamentally different from "immune boosters" and gives it a specific therapeutic role in conditions characterized by immune dysfunction or paralysis.
Thymosin alpha-1 is marketed by SciClone Pharmaceuticals (and subsequent licensees, primarily in China). It has been used clinically since the 1990s.
Forms
Available forms & half-lives
| Form | Approximate half-life |
|---|---|
| Subcutaneous injection (Zadaxin, thymalfasin) | ~2 hours |
What it does
Main effects
- Chronic hepatitis B treatment: strongest evidence base; multiple RCTs and meta-analyses; effective as monotherapy or in combination with interferon-alpha or modern antivirals (entecavir, tenofovir) PMID: 33076834 PMID: 17075991
- Sepsis mortality reduction (immune paralysis): 2016 meta-analysis of 19 RCTs showed RR 0.59 mortality reduction PMC: 5025565; 2025 TESTS trial in BMJ (1,106 patients) is the strongest controlled evidence to date
- Restoration of impaired immune function in immunocompromised hosts: TLR9-mediated activation of plasmacytoid dendritic cells; enhanced Th1 responses; increased NK cell activity; modulated regulatory T-cell function
- Vaccine response enhancement in immunocompromised populations (elderly, renal dialysis patients, others)
- Adjunctive cancer therapy: investigated for melanoma, hepatocellular carcinoma, lung cancer; signals of activity but not registration-grade
- Chronic hepatitis C historical efficacy: largely supplanted by direct-acting antivirals
- Immunomodulatory rather than immunostimulatory: restores impaired immune responses without driving inflammatory excess in healthy hosts (this is a clinically meaningful distinction)
What to watch for
Common side effects
- Unusually favorable safety profile for an actively used peptide therapeutic: 30+ clinical trials, 11,000+ subjects, 30+ years of international clinical use
- Mild injection site reactions (pain, redness): most common reported adverse effect; typically mild and self-limited
- Mild constitutional symptoms (fatigue, headache, occasional low-grade fever): notably milder than with interferon-alpha
- Transient liver enzyme elevations: sometimes seen in hepatitis B patients
- No significant hematologic toxicity: unlike interferon, does not cause neutropenia or thrombocytopenia
- No significant cardiovascular adverse effects documented in clinical trials
- Theoretical autoimmune disease risk: given immunomodulatory mechanism; rare cases reported but not consistently linked to Tα1
- Rare hypersensitivity reactions
- Less useful in healthy individuals: no immune dysfunction to correct; the framework that supports use as a "general immune booster" is not supported by evidence
- US access restricted: not FDA-approved; 2023 FDA compounding restrictions further limit US legal supply; unregulated sources have standard quality concerns (identity, purity, sterility)
- Cancer indication not established: should not substitute for evidence-based cancer therapy
Key facts
Key facts worth knowing
- Thymosin alpha-1 is a 28-amino acid peptide identical in sequence to the naturally occurring Tα1 produced by the thymus gland. It was first isolated from thymus extract in the early 1970s by Allan Goldstein and colleagues at George Washington University.
- The compound is marketed globally as Zadaxin (thymalfasin) by SciClone Pharmaceuticals (later acquired by various entities operating primarily in China). It has been used clinically since the 1990s and is approved in over 35 countries including China, Italy, India, South Korea, Philippines, Mexico, multiple South American and Middle Eastern countries.
- Mechanism is immunomodulatory rather than immunostimulatory. Thymosin alpha-1 binds toll-like receptor 9 (TLR9) on plasmacytoid dendritic cells, activating innate immune responses, promoting T-helper 1 (Th1) responses, enhancing natural killer (NK) cell activity, and modulating regulatory T-cell function. The net effect is to restore impaired immune responses in immunocompromised hosts without driving inflammatory excess in healthy hosts.
- Strongest evidence base is in chronic viral hepatitis. Multiple RCTs have demonstrated efficacy in chronic hepatitis B, particularly in combination with interferon-alpha or modern antivirals like entecavir. A 2020 meta-analysis evaluated entecavir + thymosin alpha-1 vs entecavir monotherapy in HBV-related cirrhosis with favorable results. PMID: 33076834PMID: 17075991
- Sepsis evidence is mixed but generally positive. A 2016 meta-analysis of 19 RCTs in 530 patients showed significant mortality reduction (RR 0.59, 95% CI 0.45–0.77, P=0.0001). The 2025 TESTS trial in BMJ enrolled 1,106 sepsis patients and represents the strongest controlled evidence to date. PMC: 5025565PMID: 25532482
- The FDA gap is commercial, not scientific. Multiple sources document that thymosin alpha-1 has not been submitted for FDA approval despite extensive global evidence. The reasons are typically described as commercial: limited US market opportunity (HBV more prevalent in Asia), complexity of regulatory submission, and pharmaceutical company decisions about resource allocation. In 2023, the FDA placed additional restrictions on thymosin alpha-1 compounding in the United States, limiting one previous legal access channel.
- WADA status: Not currently prohibited (thymosin alpha-1 is not on the WADA Prohibited List). This distinguishes it from TB-500/thymosin beta-4 (which is prohibited).
Legal status
Legal status
Not FDA-approved in the United States. Approved in 35+ countries. Subject to FDA compounding restrictions since 2023. Available through international pharmaceutical channels in approved jurisdictions; obtainable in the US primarily through unregulated sources or specialty compounding (legally restricted). Not a controlled substance. Not WADA-prohibited.